title: Effect of halofuginone on the development of tight skin (TSK) syndrome.
abstract: The end point of pathogenic events in scleroderma is fibrosis of the skin and internal organs. Fibrosis in scleroderma results from the over synthesis and deposition of collagen in the connective tissue. The morbidity and mortality of the scleroderm is very high and presently there is no specific treatment. Halofuginone is a drug with great potential for the treatment of scleroderma since it inhibits the synthesis of collagen type I by fibroblasts. We have studied the in vivo effect of halofuginone in tight skin (TSK) mice that spontaneously develop a scleroderma-like disease due to a genetic defect. Our results demonstrate that halofuginone prevented the occurrence of skin sclerosis when administered to newborn mice and reduced cutaneous hyperplasia when administered in adult TSK mice. These effects correlated with a decreased number of cells synthesizing collagen gene transcripts and a reduction in the level of autoantibodies specific for human target antigens. These results indicate that halofuginone may have use as a therapeutic in the treatment of fibrotic disease.
authors.affiliation: Department of Microbiology, The Mount Sinai School of Medicine, Box 1124, One Gustave L Levy Place, New York NY 10029, USA.
authors.forename: Tracy
authors.initials: T
authors.lastname: McGaha
authors.forename: Takao
authors.initials: T
authors.lastname: Kodera
authors.forename: Robert
authors.initials: R
authors.lastname: Phelps
authors.forename: Harry
authors.initials: H
authors.lastname: Spiera
authors.forename: Mark
authors.initials: M
authors.lastname: Pines
authors.forename: Constantin
authors.initials: C
authors.lastname: Bona
mesh_terms: D000818:Animals; D000831:Animals, Newborn; D003094:Collagen / Q000378:metabolism; D004195:Disease Models, Animal; D005355:Fibrosis / Q000188:drug therapy; D006801:Humans; D051379:Mice; D008810:Mice, Inbred C57BL; D008817:Mice, Mutant Strains; D010880:Piperidines; D011500:Protein Synthesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D011799:Quinazolines / Q000008:administration & dosage / Q000627:therapeutic use*; D052999:Quinazolinones; D012595:Scleroderma, Systemic / Q000188:drug therapy* / Q000517:prevention & control*; D012871:Skin Diseases / Q000188:drug therapy / Q000517:prevention & control
chemical_list: D010880:Piperidines; D011500:Protein Synthesis Inhibitors; D011799:Quinazolines; D052999:Quinazolinones; D003094:Collagen; C010176:halofuginone